(28 days)
No
The summary describes a mechanical access system (sheath and dilator) and does not mention any software, algorithms, or data processing that would indicate the use of AI/ML.
No
The device provides access for another therapeutic device (WATCHMAN FLX Left Atrial Appendage Closure Device) but does not directly perform a therapeutic function itself.
No
The device is an access system (sheath and dilator) used to facilitate the delivery of another device (WATCHMAN FLX Left Atrial Appendage Closure Device). Its purpose is to provide "vascular and transseptal access," not to diagnose a condition or disease.
No
The device description explicitly states it is composed of an Access Sheath and Dilator, which are physical hardware components.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections. They are used to provide information for diagnosis, monitoring, or screening.
- Device Function: The WATCHMAN FXD Curve™ Access System is described as a system used to provide vascular and transseptal access for another device (the WATCHMAN FLX Left Atrial Appendage Closure Device). This involves physically accessing internal structures of the body.
- Lack of Sample Analysis: There is no mention of this device analyzing any biological samples or performing any diagnostic tests on samples taken from the patient. Its function is purely procedural – facilitating access for another medical device.
Therefore, the WATCHMAN FXD Curve™ Access System is a medical device used for a procedural purpose, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The WATCHMAN FXD Curve™ Access System is intended to provide vascular and transseptal access for the WATCHMAN™ FLX™ Left Atrial Appendage Closure Device with Delivery System.
Product codes
DOY, DQY
Device Description
The Boston Scientific WATCHMAN FXD Curve™ Access System is composed of an Access Sheath and Dilator. The WATCHMAN FXD Curve Access System is used to provide vascular and transseptal access for WATCHMAN™ FLX™ Left Atrial Appendage Closure Device with Delivery System. The WATCHMAN FXD Curve Access System will be used by interventional cardiologists and/or electrophysiologists who are trained in percutaneous and transseptal procedures.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
interventional cardiologists and/or electrophysiologists who are trained in percutaneous and transseptal procedures.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Design verification testing was performed to support a determination of substantial equivalence to WATCHMAN TruSeal Access System per Class II Special Controls Guidance Document for Certain Percutaneous Transluminal Coronary Angioplasty (PTCA) Catheters, September 2010. The WATCHMAN FXD Curve Access System also conforms to relevant sections of EN ISO 10555-1, Sterile, Single-Use Intravascular Catheters; Part 1: General Requirements. Based on the indications for use / intended use, design, and safety and performance testing, the WATCHMAN FXD Curve Access System meets the requirements for its intended use and is substantially equivalent to the predicate device.
The following device performance tests were completed:
• Dimensional Characterization
• Curve Shape
• Proximal and Distal Marker Location
• Sheath Force Transmission
• Kink Resistance
• Tip Deflection
• Torqueability
• Radiopacity
• Tensile
• Surface
• Leak-Free Conduits
• Pressure Retention
• Particulates
• Access Sheath Cap Detachment Force
• Access System Smooth Transition
The following biocompatibility tests were completed:
• Cytotoxicity
• Sensitization
• Intracutaneous Reactivity
• Acute Systemic Toxicity
• Complement Activation
• Materials Mediated Pyrogenicity
• Hemolysis Direct Contact
• Hemolysis Extract Method
• In Vitro Platelet and Leukocyte Count
• Partial Thromboplastin Time
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.1250 Percutaneous catheter.
(a)
Identification. A percutaneous catheter is a device that is introduced into a vein or artery through the skin using a dilator and a sheath (introducer) or guide wire.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
August 13, 2021
Boston Scientific Corporation Alexa Keenan Regulatory Affairs Specialist II Three Scimed Place Maple Grove, Minnesota 55311-1566
Re: K212228
Trade/Device Name: WATCHMAN FXD Curve™ Access System Regulation Number: 21 CFR 870.1250 Regulation Name: Percutaneous Catheter Regulatory Class: Class II Product Code: DOY Dated: July 15, 2021 Received: July 16, 2021
Dear Alexa Keenan:
We have reviewed vour Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal
1
statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE(@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Rachel E. Neubrander -S
Rachel Neubrander Assistant Director DHT2B: Division of Circulatory Support, Structural and Vascular Devices Office of Product Evaluation and Ouality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K212228
Device Name WATCHMAN FXD Curve™ Access System
Indications for Use (Describe)
The WATCHMAN FXD Curve Access System is intended to provide vascular and transseptal access for the WATCHMAN FLX Left Atrial Appendage Closure Device with Delivery System.
Type of Use (Select one or both, as applicable)
| Prescription Use (Part 21 CFR 801 Subpart D) |
|---|
| Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/0 description: The image shows the alphanumeric string "K212228" in a simple, sans-serif font. The characters are uniformly sized and spaced, creating a clear and legible sequence. The text is presented in black against a plain white background, ensuring high contrast and readability.
Boston Scientific Corporation
300 Boston Scientific Way
Marlborough, MA 01752 (508) 683-4000 www.bostonscientific.com
510(k) Summary
Per 21 CFR §807.92
Per 21 CFR §807.92
| Sponsor: | Boston Scientific Corporation
300 Boston Scientific Way
Marlborough, Massachusetts 01752
USA | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Contact Name and
Information | Alexa M Keenan
Three Scimed Place
Maple Grove MN, 55311-1566
Phone: 763-494-1731
Fax: 763-494-2222
e-mail: Alexa.Keenan@bsci.com | |
| Date Prepared: | July 15, 2021 | |
| Proprietary Name | WATCHMAN FXD Curve™ Access System | |
| Common Name | Catheter, Percutaneous | |
| Product Code | DQY | |
| Classification | Class II, 21 CFR Part 870.1250 | |
| Predicate Device | WATCHMAN™ TruSeal™ Access System, K180864, cleared
20 July 2018 | |
| Device Description | The Boston Scientific WATCHMAN FXD Curve™ Access System is composed of an Access Sheath and Dilator. The WATCHMAN FXD Curve Access System is used to provide vascular and transseptal access for WATCHMAN™ FLX™ Left Atrial Appendage Closure Device with Delivery System. The WATCHMAN FXD Curve Access System will be used by interventional cardiologists and/or electrophysiologists who are trained in percutaneous and transseptal procedures. | |
| Indications for Use /
Intended Use | The WATCHMAN FXD Curve™ Access System is intended to provide vascular and transseptal access for the WATCHMAN™ FLX™ Left Atrial Appendage Closure Device with Delivery System. | |
| Device Technology
Characteristics and
Comparison to
Predicate Device | WATCHMAN FXD Curve Access System incorporates
substantially equivalent design, packaging, fundamental
technology, manufacturing processes, sterilization process, and
indications for use / intended use as those featured in
WATCHMAN TruSeal Access System, K180864. | |
| Non-Clinical
Performance Data | Design verification testing was performed to support a
determination of substantial equivalence to WATCHMAN
TruSeal Access System per Class II Special Controls Guidance
Document for Certain Percutaneous Transluminal Coronary
Angioplasty (PTCA) Catheters, September 2010. The
WATCHMAN FXD Curve Access System also conforms to
relevant sections of EN ISO 10555-1, Sterile, Single-Use
Intravascular Catheters; Part 1: General Requirements. Based
on the indications for use / intended use, design, and safety and
performance testing, the WATCHMAN FXD Curve Access
System meets the requirements for its intended use and is
substantially equivalent to the predicate device. | |
| The following device performance tests were completed:
• Dimensional Characterization
• Curve Shape
• Proximal and Distal Marker Location
• Sheath Force Transmission
• Kink Resistance
• Tip Deflection
• Torqueability
• Radiopacity | • Tensile
• Surface
• Leak-Free Conduits
• Pressure Retention
• Particulates
• Access Sheath Cap Detachment Force
• Access System Smooth Transition | |
| The following biocompatibility tests were completed:
• Cytotoxicity
• Sensitization
• Intracutaneous Reactivity
• Acute Systemic Toxicity
• Complement Activation | | • Materials Mediated Pyrogenicity
• Hemolysis Direct Contact
• Hemolysis Extract Method
• In Vitro Platelet and Leukocyte Count
• Partial Thromboplastin Time |
| Clinical Testing | Clinical evaluation was not required for this device. | |
| Conclusion | The results of all testing demonstrate that the WATCHMAN FXD
Curve Access System is substantially equivalent to the
WATCHMAN TruSeal Access System, K180864. | |
4